Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
UK parliament backs EU trade deal, as industry sifts through detailThe post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some Share XUK parliament backs EU trade deal, as industry sifts through detailhttps://pharmaphorum.com/news/uk-parliament-backs-eu-trade-deal-as-industry-sifts-through-detail/
Roche claims EU okay for Herceptin/Perjeta combination PhesgoRoche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta Share XRoche claims EU okay for Herceptin/Perjeta combination Phesgohttps://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/
UK, EU agree Northern Ireland medicines, food border controlsThe UK and EU have reached an agreement on border checks for Northern Ireland that should guarantee that Share XUK, EU agree Northern Ireland medicines, food border controlshttps://pharmaphorum.com/news/uk-eu-agree-northern-ireland-medicines-food-border-controls/
The calm after the storm: How COVID-19 is making pharma more resilientCOVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning Share XThe calm after the storm: How COVID-19 is making pharma more resilienthttps://pharmaphorum.com/views-analysis-sales-marketing/the-calm-after-the-storm-how-covid19-is-making-pharma-more-resilient-and-accessible/
EU ramps up supply of COVID-19 vaccine, drugsThe European Commission has taken its advance orders for potential COVID-19 vaccines to more than 1.1 billion, after Share XEU ramps up supply of COVID-19 vaccine, drugshttps://pharmaphorum.com/news/eu-ramps-up-supply-of-covid-19-vaccine-drugs/
Life science leaders sign new ‘Biotech Social Pact’ for EuropeThe signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a Share XLife science leaders sign new ‘Biotech Social Pact’ for Europehttps://pharmaphorum.com/views-analysis-market-access/life-science-leaders-sign-new-biotech-social-pact-for-europe/
Alnylam’s Anant Murthy on making it as a US biotech in EuropeAlnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how Share XAlnylam’s Anant Murthy on making it as a US biotech in Europehttps://pharmaphorum.com/r-d/views-analysis-r-d/alnylam-anant-murthy-on-making-it-as-a-us-biotech-in-europe/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
